Rani Therapeutics raises $3mln in registered direct offering.

Rani Therapeutics has entered into a securities purchase agreement with a single institutional investor for the purchase of 4,354,000 shares of Class A common stock at $0.40 per share and pre-funded warrants to purchase 3,146,000 shares at $0.3999 per share. The offering is expected to close on July 16, 2025, with gross proceeds of approximately $3.0 million. Maxim Group LLC is acting as the sole placement agent.

SAN JOSE, Calif., July 15, 2025 -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has entered into a securities purchase agreement with a single institutional investor. The company will sell 4,354,000 shares of its Class A common stock at $0.40 per share and pre-funded warrants to purchase 3,146,000 shares at $0.3999 per share in a registered direct offering. The offering is expected to close on or about July 16, 2025, subject to customary closing conditions.

Maxim Group LLC is acting as the sole placement agent for the offering. The gross proceeds to Rani Therapeutics from this offering are expected to be approximately $3.0 million, before deducting placement agent fees and other offering expenses, excluding the proceeds, if any, from the exercise of the pre-funded warrants.

The securities in the registered direct offering are being offered and sold by Rani pursuant to a "shelf" registration statement on Form S-3 (File No. 333-266444) which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 10, 2022. The offering of the securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The company has developed the RaniPill® capsule, a novel, proprietary, and patented platform technology intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using RaniPill® capsule technology.

Investor Contact: investors@ranitherapeutics.com
Media Contact: media@ranitherapeutics.com

References:
[1] https://www.globenewswire.com/news-release/2025/07/15/3115645/0/en/Rani-Therapeutics-Holdings-Inc-Announces-Pricing-of-3-0-Million-Registered-Direct-Offering.html
[2] https://www.stocktitan.net/news/RANI/rani-therapeutics-and-pro-gen-announce-late-breaking-presentation-at-0r959w1ty5ph.html
[3] https://www.stocktitan.net/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-3-0-million-bkhouzv7720r.html